Rhythm Pharmaceuticals (NASDAQ:RYTM) reported Phase 3 top-line results from its EMANATE trial evaluating setmelanotide in four heterozygous genetic cohorts linked to MC4R pathway dysfunction, with com ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results